Nascent Biotech, Inc.
Other OTCTotal Valuation
Nascent Biotech, Inc. carries a market capitalization of 103,330.00, placing it among publicly traded companies globally.
| Market Cap | 103,330.00 |
| Enterprise Value | N/A |
Share Statistics
Nascent Biotech, Inc. currently has 172.20M shares outstanding.
| Shares Outstanding | 172.20M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
| PE Ratio | N/A |
| PS Ratio | N/A |
| PB Ratio | -0.59 |
| P/TBV Ratio | -28.01 |
| P/FCF Ratio | -10.69 |
| P/OCF Ratio | -10.69 |
Financial Position
Nascent Biotech, Inc. maintains a current ratio of 0.31, meaning it holds 0.3x the short-term assets needed to cover near-term liabilities.
| Current Ratio | 0.31 |
| Quick Ratio | 0.06 |
| Debt / Equity | N/A |
| Debt / EBITDA | N/A |
| Interest Coverage | -14.00 |
Financial Efficiency
| Return on Equity (ROE) | N/A |
| Return on Assets (ROA) | -1,256.79 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | N/A |
Stock Price Statistics
Nascent Biotech, Inc.'s stock has declined approximately -70% over the past 52 weeks. The 50-day moving average sits at 0.00, while the 200-day moving average is 0.00.
| Beta (5Y) | N/A |
| 52-Week Price Change | -70% |
| 50-Day Moving Average | 0.00 |
| 200-Day Moving Average | 0.00 |
| Average Volume (20 Days) | N/A |
Income Statement
EBITDA reached -2.09M, while operating income came in at -2.09M.
| Revenue | N/A |
| Gross Profit | N/A |
| Operating Income | -2.09M |
| Pretax Income | -1.92M |
| Net Income | -1.92M |
| EBITDA | -2.09M |
| EBIT | -2.09M |
| Earnings Per Share (EPS) | -0.01 |
Balance Sheet
Total book value stands at -24.47M, with working capital of -514,540.00 providing operational flexibility.
| Cash & Cash Equivalents | 47,391.00 |
| Total Debt | N/A |
| Net Debt | 11,609.00 |
| Equity (Book Value) | -24.47M |
| Book Value Per Share | -0.15 |
| Working Capital | -514,540.00 |
Cash Flow
Nascent Biotech, Inc. produced -1.35M in operating cash flow over the past twelve months.
| Operating Cash Flow | -1.35M |
| Capital Expenditures | N/A |
| Free Cash Flow | -1.35M |
| FCF Per Share | -0.01 |
Dividends & Yields
| Dividend Per Share | N/A |
| Dividend Yield | N/A |
| Payout Ratio | N/A |
| Shareholder Yield | -9.62 |
| FCF Yield | -9.35 |
Scores
Nascent Biotech, Inc. posts an Altman Z-Score of -173.13, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | -173.13 |